Affordable Access

Publisher Website

P327: A situational analysis of pharmacovigilance in republic of benin based on the Artemisinin-based Combination Therapies (ACTs)

Authors
Journal
Antimicrobial Resistance and Infection Control
2047-2994
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Identifiers
DOI: 10.1186/2047-2994-2-s1-p327
Keywords
  • Poster Presentation
Disciplines
  • Pharmacology

Abstract

P327: A situational analysis of pharmacovigilance in republic of benin based on the Artemisinin-based Combination Therapies (ACTs) POSTER PRESENTATION Open Access P327: A situational analysis of pharmacovigilance in republic of benin based on the Artemisinin- based Combination Therapies (ACTs) A Aurel Constant1*, N Jude2, M Achille3, H Yves4 From 2nd International Conference on Prevention and Infection Control (ICPIC 2013) Geneva, Switzerland. 25-28 June 2013 Introduction To assess Benin’s pharmacovigilance system, identify the gaps and define strategy which could lead to its functional establishment, structure questionnaires was applied to investigate physicians, pharmacists and pharmaceutical industry representatives’ knowledge, attitude and practice regarding Adverse Drug Reactions (ADRs) reporting. Methods Indicator-based Pharmacovigilance Assessment Tool (IPAT) was also used to assess the current landscape with different stakeholders. Results 30.77% physicians and 31.11% pharmacists acknowledged that they faced at least one time ADRs suspected to be associated with antimalarial drug (P-value < 0.01). How- ever none of the physicians or the pharmacists has ever reported ADRs to the national pharmacovigilance service. The main reasons for not reporting were ‘‘yellow card not available’’ and “not aware about the existence of pharma- covigilance center”. 6.97 % of representatives of the phar- maceutical companies monitored the safety of their products and none of them have ever reported ADRs to the health authority (DPM). In return, none of the labora- tories have ever received a report related to quality or ADRs related to their drugs on the market from DPM. IPAT led to low overall scores indicating that there is no functional pharmacovigilance system in place. The major shortcoming is the lack of expertise in pharmacovigilance despite the availability of qualified human resource in the country. Conclusion There is a need to identify and implement adequate human resourc

There are no comments yet on this publication. Be the first to share your thoughts.